Russell Investments Group Ltd. Has $713,000 Stake in 10x Genomics $TXG

Key Points

• Russell Investments Group Ltd. increased its stake in 10x Genomics by 385.6%, acquiring an additional 64,851 shares, bringing its total ownership to 81,669 shares valued at approximately $713,000.
• 10x Genomics reported $0.28 earnings per share for the most recent quarter, surpassing analyst expectations of ($0.35) and achieving a revenue of $172.91 million.
• Wall Street analysts have mixed ratings on 10x Genomics, with six equities analysts recommending a Buy, six a Hold, and one a Sell, reflecting uncertainty in stock performance.

Russell Investments Group Ltd. grew its stake in 10x Genomics (NASDAQ:TXG - Free Report) by 385.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 81,669 shares of the company's stock after acquiring an additional 64,851 shares during the period. Russell Investments Group Ltd. owned 0.07% of 10x Genomics worth $713,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. ARK Investment Management LLC lifted its holdings in 10x Genomics by 7.5% during the 1st quarter. ARK Investment Management LLC now owns 12,845,713 shares of the company's stock worth $112,143,000 after buying an additional 901,656 shares in the last quarter. Vanguard Group Inc. boosted its holdings in 10x Genomics by 1.7% in the first quarter. Vanguard Group Inc. now owns 11,118,086 shares of the company's stock valued at $97,061,000 after acquiring an additional 184,537 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in 10x Genomics by 10.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,116,573 shares of the company's stock worth $30,394,000 after purchasing an additional 193,588 shares during the period. Voloridge Investment Management LLC lifted its position in 10x Genomics by 12.1% during the 4th quarter. Voloridge Investment Management LLC now owns 1,585,965 shares of the company's stock valued at $22,774,000 after purchasing an additional 171,161 shares during the period. Finally, Two Sigma Investments LP grew its position in shares of 10x Genomics by 291.2% during the 4th quarter. Two Sigma Investments LP now owns 1,319,487 shares of the company's stock worth $18,948,000 after buying an additional 982,203 shares during the period. 84.68% of the stock is owned by institutional investors.

10x Genomics Stock Up 1.7%

Shares of NASDAQ:TXG traded up $0.23 during mid-day trading on Thursday, reaching $13.57. 1,709,156 shares of the stock were exchanged, compared to its average volume of 2,840,047. The stock's 50 day simple moving average is $13.10 and its 200-day simple moving average is $10.74. 10x Genomics has a one year low of $6.78 and a one year high of $24.38. The company has a market cap of $1.69 billion, a P/E ratio of -19.39 and a beta of 2.00.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.63. The firm had revenue of $172.91 million during the quarter, compared to the consensus estimate of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The business's revenue was up 12.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. Analysts anticipate that 10x Genomics will post -1.43 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft set a $14.00 price objective on shares of 10x Genomics and gave the company a "hold" rating in a research note on Friday, August 8th. Wall Street Zen raised 10x Genomics from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Stephens reiterated an "overweight" rating and issued a $14.00 price objective on shares of 10x Genomics in a report on Thursday, May 15th. The Goldman Sachs Group reduced their target price on 10x Genomics from $7.50 to $6.50 and set a "sell" rating on the stock in a report on Monday, May 12th. Finally, Canaccord Genuity Group set a $16.00 price target on 10x Genomics in a research note on Monday, August 11th. Six equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $13.54.

Insider Buying and Selling

In related news, insider Benjamin J. Hindson sold 7,486 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $103,231.94. Following the completion of the transaction, the insider directly owned 440,888 shares of the company's stock, valued at approximately $6,079,845.52. This represents a 1.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Adam Taich sold 22,315 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $307,723.85. Following the sale, the chief financial officer owned 309,273 shares in the company, valued at approximately $4,264,874.67. This represents a 6.73% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 39,149 shares of company stock worth $539,865. Corporate insiders own 9.39% of the company's stock.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.